Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues

Medical Microbiology and Immunology

Volumn 197, Issue 2, 2008, Pages 151-158

  Wirtz, Nikolaus ^a   Schader, Sina I ^a   Holtappels, Rafaela ^a   Simon, Christian O ^a   Lemmermann, Niels A W ^a   Reddehase, Matthias J ^a   Podlech, Jürgen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antiserum; Antiviral antibodies; B cells; B cell deficient mouse mutant; Cytomegalovirus; Hematopoietic stem cell transplantation (HSCT); Immunodominant epitope; Immunotherapy; Serum transfer; Virus cell to cell spread; Virus dissemination; Virus latency

Indexed keywords

ANTISERUM; CYTOMEGALOVIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; IMMUNE STATUS; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CYTOMEGALOVIRUS; IMMUNOCOMPROMISED HOST; LIVER; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTRALIZATION TESTS;

EID: 42249090708     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-008-0095-0     Document Type: Article

References (28)

1. Mach M (2006) Antibody-mediated neutralization of infectivity. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 265-283
2. Pepperl-Klindworth S, Plachter B (2006) Current perspectives in vaccine development. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 551-572
3. Britt WJ (1996) Vaccines against human cytomegalovirus: time to test. Trends Microbiol 4:34-38
4. Gonczol E, Plotkin S (2001) Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 1:401-412
5. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee (2004) Vaccine development to prevent cytomegalovirus disease: report from the national vaccine advisory committee. Clin Infect Dis 39:233-239
6. Emery VC (1998) Relative importance of cytomegalovirus load as a risk factor for cytomegalovirus disease in the immunocompromised host. In: Scholz M, Rabenau HF, Doerr HW, Cinatl J Jr (eds) Monographs in virology, vol 21: CMV-related immunopathology. Karger, Basel, pp 288-301
7. Araullo-Cruz TP, Ho M, Armstrong JA (1978) Protective effect of early serum from mice after cytomegalovirus infection. Infect Immun 21:840-842
8. Shanley JD, Jordan MC, Stevens JG (1981) Modification by adoptive humoral immunity of murine cytomegalovirus infection. J Infect Dis 143:231-237
9. Gorman S, Harvey NL, Moro D, Lloyd ML, Voigt V, Smith LM, Lawson MA, Shellam GR (2006) Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87:1123-1132
10. Dix RD, Cray C, Cousins SW (1987) Antibody alone does not prevent experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency (MAIDS). Ophthalmic Res 29:381-392
11. Kitamura D, Roes J, Kühn R, Rajewsky K (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423-426
12. Reddehase MJ, Balthesen M, Rapp M, Jonjić S, Pavić I, Koszinowski UH (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185-193
13. Jonjić S, Pavić I, Polić B, Crnković I, Lucin P, Koszinowski UH (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713-1717
14. Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjić S, Messerle M, Bradel-Tretheway B, Winkler TH, Mach M (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472-3479
15. Reddehase MJ (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2:831-844
16. Holtappels R, Munks WM, Podlech J, Reddehase MJ (2006) CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 383-418
17. Streblow DN, Varnum SM, Smith RD, Nelson JA (2006) A proteomics analysis of human cytomegalovirus particles. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 91-110
18. Holtappels R, Thomas D, Podlech J, Reddehase MJ (2002) Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J Virol 76:151-164
19. Erlach KC, Böhm V, Seckert CK, Reddehase MJ, Podlech J (2006) Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection. J Virol 80:4801-4819
20. Podlech J, Holtappels R, Grzimek NKA, Reddehase MJ (2002) Animal models: murine cytomegalovirus. In: Kaufmann SHE, Kabelitz D (eds) Methods in microbiology 32. Immunology of infection. Academic Press, San Diego, pp 493-525
21. Simon CO, Holtappels R, Tervo HM, Böhm V, Däubner T, Oehrlein-Karpi SA, Kühnapfel B, Renzaho A, Strand D, Podlech J, Reddehase MJ, Grzimek NK (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436-10456
22. Podlech J, Holtappels R, Wirtz N, Steffens HP, Reddehase MJ (1998) Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol 79:2099-2104
23. Sacher T, Podlech J, Mohr AC, Jordan S, Ruzsics Z, Reddehase MJ, Koszinowski UH (2008) The major virus producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host Microbe (in press)
24. Noda S, Aguirre SA, Bitmansour A, Brown JM, Sparer TE, Huang J, Mocarski ES (2006) Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood 107:30-38
25. Mocarski ES, Hahn G, White KL, Xu J, Slobedman B, Hertel L, Aguirre SA, Noda S (2006) Myeloid cell recruitment and function in pathogenesis and latency. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 465-481
26. Ménard C, Wagner M, Ruzsics Z, Holak K, Brune W, Campbell AE, Koszinowski UH (2003) Role of murine cytomegalovirus US22 gene family members in replication in macrophages. J Virol 77:5557-5570
27. Čičin-Šain L, Podlech J, Messerle M, Reddehase MJ, Koszinowski UH (2005) Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J Virol 79:9492-9502
28. Čičin-Šain L, Ruzsics Z, Podlech J, Bubić I, Ménard C, Jonjić S, Reddehase MJ, Koszinowski UH (2008) Dominant-negative FADD rescues the in vivo fitness of a cytomegalovirus lacking an anti-apoptotic viral gene. J Virol 82:2056-2064